Roberto Iacone, MD, PhD

Entrepreneur in Residence, Basel, Switzerland

Roberto is a physician-scientist and a serial entrepreneur. He most recently served as Entrepreneur-in-Residence for the Versant Ventures group where he co-founded Bright Peak Therapeutics and Ridgeline Therapeutics, Versant's Basel-based Discovery Engine. He was responsible for sourcing and evaluating academic opportunities from European institutes, and for leading biology and translational activities for Ridgeline NewCos. He was part of the leadership team which built the precision oncology Black Diamond Therapeutics from inception through multiple financing rounds and recent NASDAQ IPO.

Prior to his role at Versant Venture, Roberto spent over 9 years of industry experience in preclinical research and early development at Roche, having managed discovery programs across a range of therapeutic areas including Neuroscience, Ophthalmology and Rare Diseases. He most recently served as Roche's Global Head of Rare Diseases Research, and established numerous external collaborations with academic and biotech partners, which included large, small molecule and gene therapy programs. Roberto holds an M.D. from the University of Napoli, a Ph.D. from the Max Planck Research School for Molecular Cell Biology and Genetics.